Abstract
Patients with schizophrenia have a shorter life expectancy and their risk of dying from a cardiovascular disease is higher than the general population. Both facts have been attributed to the raised presence of metabolic syndrome. There is a big amount of scientific publications that deals with the relationship between schizophrenia, antipsychotic treatment, and the development of metabolic syndrome. There is also information about recommendations and clinical guides to achieve an adequate prevention, screening, and treatment of the disease. The aim of this review is to update the current information about this issue and to understand related etiologic factors, differences between antipsychotic drugs, and the current recommendations for patient's care.
Copyright © 2012 Elsevier España, S.L. All rights reserved.
MeSH terms
-
Antipsychotic Agents / adverse effects*
-
Antipsychotic Agents / therapeutic use
-
Benzodiazepines / adverse effects
-
Benzodiazepines / therapeutic use
-
Blood Glucose / analysis
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / mortality
-
Clozapine / adverse effects
-
Clozapine / therapeutic use
-
Comorbidity
-
Follow-Up Studies
-
Humans
-
Hypothalamus / drug effects
-
Hypothalamus / physiopathology
-
Incidence
-
Life Expectancy
-
Lipid Metabolism / drug effects
-
Metabolic Syndrome / chemically induced*
-
Metabolic Syndrome / drug therapy
-
Metabolic Syndrome / epidemiology
-
Metabolic Syndrome / physiopathology
-
Metabolic Syndrome / prevention & control
-
Obesity, Abdominal / chemically induced
-
Obesity, Abdominal / epidemiology
-
Olanzapine
-
Practice Guidelines as Topic
-
Schizophrenia / drug therapy*
-
Schizophrenia / epidemiology
-
Weight Gain
Substances
-
Antipsychotic Agents
-
Blood Glucose
-
Benzodiazepines
-
Clozapine
-
Olanzapine